Results 131 to 140 of about 1,087 (181)

Academia, industry and the slow adoption of new treatments. [PDF]

Brain
Klein P, Pong A, Koepp M, Löscher W, Sander JW, Faught E.   +5 more
europepmc   +1 more source

Antiseizure Medications in Development: Novel Mechanisms, Precision Therapy, and the Move Towards Disease Modification. [PDF]

Curr Issues Mol Biol
Martins WA.
europepmc   +1 more source

Ranking of antiseizure medications in a panel of focal seizure models predicts their comparative efficacy in clinical add-on trials in drug-resistant focal epilepsy. [PDF]

Epilepsia
Löscher W, Klein P.
europepmc   +1 more source

Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift? [PDF]

Neurol Ther
Dono F, Russo M, Agosto R, Evangelista G, Nucera B, Falcicchio G, Sensi SL.   +6 more
europepmc   +1 more source

Individual Alpha Frequency as an EEG Biomarker of Drug-Related Cognitive Burden in Epilepsy. [PDF]

Eur J Neurol
Assenza G, Sancetta BM, Lippa G, Nesta M, Ricci L, Liguori C, Testone G, Fernandes M, Di Mauro G, Di Lazzaro V, Tombini M.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cenobamate for the Treatment of Focal Epilepsies

Expert Opinion on Pharmacotherapy, 2020
Antiseizure drugs (ASDs) play a central and crucial role in the treatment of epilepsy patients because the majority require anticonvulsant treatment for an extended period of time. Due to the fact that 30% of patients are refractory to medical treatment, new therapeutic options are necessary.
Adam Strzelczyk, Catrin Mann, Sebastian Bauer   +2 more
exaly   +3 more sources

Effects of Cenobamate on Cognitive Performance of Epilepsy Patients

Seizure: the Journal of the British Epilepsy Association, 2022
Cenobamate (CNB) is a new antiseizure medication (ASM) for the treatment of focal epilepsy in adults. While efficacy of CNB was confirmed in controlled clinical trials, its effects on cognition are unclear. Cognitive adverse effects of ASM affect quality of life and retention rate. Therefore, we investigated whether the adjunctive treatment with CNB is
Marcel Heers, Birgitta Metternich, Dirk-Matthias Altenmüller   +2 more
exaly   +4 more sources

Adjunctive Cenobamate in Highly Active and Ultra-Refractory Focal Epilepsy: A “Real-World” Retrospective Study

Epilepsia, 2023
Objective: Recent clinical trials have shown that cenobamate substantially improves seizure control in focal-onset drug-resistant epilepsy (DRE). However, little is known about cenobamate's performance in highly active (≥20 seizures/month) and ultra ...
Hany El Naggar, Norman Delaney, Patrick B Moloney   +2 more
exaly   +1 more source

Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations [PDF]

Neurology and Therapy, 2022
INTRODUCTION: Our objective was to provide expert consensus recommendations to improve treatment tolerability through dose adjustments of concomitant antiseizure medications (ASMs) during addition of cenobamate to existing ASM therapy in adult patients ...
Pavel Klein, Gregory L Krauss, John M. Stern   +2 more
exaly   +2 more sources